ImageneBio Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
ImageneBio Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases. Its lead program, IMG-007, is a non-depleting anti-OX40 monoclonal antibody designed to modulate OX40 receptor signaling on activated T cells, with development centered on conditions such as atopic dermatitis and alopecia areata. The company also explores broader applications in immune-mediated disorders, reflecting a research pipeline built around differentiated treatment approaches for chronic inflammatory disease. Based in San Diego, California, ImageneBio Inc. plays a specialized role in the biotechnology market by advancing targeted antibody-based therapies aimed at improving disease control in areas with significant unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Kristin Yarema Ph.D.
- Employees
- 18
- Headquarters
- San Diego, CA, United States
- Website
- www.inmagenebio.com